• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Carbon nanotube delivery of siRNAs could prevent kidney injury [PreClinical]

byChristine YoonandJessica Lau
April 4, 2016
in Chronic Disease, Nephrology, Preclinical
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Ammonium-functionalized carbon nanotubes (fCNTs) that delivered small interfering RNAs (siRNAs) to the kidney were able to suppress expression of two target genes involved in acute kidney injury (AKI).

2. In a mouse model of AKI, fCNTs loaded with siRNAs enhanced progression-free survival and reduced fibrosis and immune infiltration of the kidney.

Evidence Rating Level: 2 (Good)           

Study Rundown: AKI, a common and deadly side effect of medical regimens like chemotherapy, currently lacks preventative and therapeutic treatments. In this work, the authors developed a prophylactic therapy for AKI by exploiting the ability for fibrillar fCNTs to carry siRNA cargo and traffic to the kidney.

In an initial test of siRNA delivery, fCNTs carrying siTrp53 or siMep1b (siRNAs targeting the p53 and meprin-1β proteins, respectively) were injected into mice for 3 consecutive days. Histological analysis of cortical kidney sections demonstrated reduced expression of p53 and meprin-1β in mice with fCNT/siRNA treatment as compared to those treated with saline or siRNA alone. To test prophylactic efficacy in a model of AKI, mice were treated with fCNTs loaded with siTrp53 and siMep1b before receiving a nephrotoxic dose of the chemotherapy drug cisplatin. Compared to the control group that received fCNT with a control siRNA, mice treated with fCNT/siTrp53/siMep1b had near normal kidney levels of p53 and meprin-1β. Treatment with fCNT/siTrp53/siMep1b also led to greater survival rates of mice for 11 days after cisplatin injury and reduced kidney fibrosis at 6 months after injury. Tissue staining for immune cells showed decreased acute and chronic immune infiltration in fCNT/siTrp53/siMep1b mice versus control mice, at 11 days and 6 months post-injury.

Overall, this study describes a novel treatment paradigm for preventing drug-induced AKI. While some general safety studies were completed in this work, more comprehensive analyses of fCNT biocompatibility and potential off-target effects are necessary before transition to clinical trials. If successful, this treatment approach could also relieve clinical drug dosage limitations due to deleterious AKI responses.

RELATED REPORTS

AI health chatbot shows no benefit for perinatal anxiety or depression

ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma

Click to read the study in Science Translational Medicine

Relevant Reading: Activation and involvement of p53 in cisplatin-induced nephrotoxicity

In-Depth [animal study]: Healthy female Balb/c mice received daily intravenous injections of fCNT/siTrp53 or fCNT/siMep1b (0.032mg at 1:1 molar ratio), siTrp53 or siMep1b alone (0.002mg each), or PBS control for 3 consecutive days. On day 4, the kidneys were harvested and sectioned for immunohistochemistry (n=3). Staining for p53 and meprin-1β  showed that delivery of siRNA with fCNTs significantly decreased the portion of p53- and meprin-1β-positive tissue, thus demonstrating improved suppression of target genes over PBS or siRNA alone controls (p<0.0001).

In the AKI model, mice were treated with fCNT/siRNA for 5 days, with cisplatin injury induced on day 3 via a 10mg/kg dose. fCNT/siTrp53/siMep1b and the control fCNT/siScram were each administered at 1.6mg fCNT + 0.087mg siRNA/kilogram. Kidneys were harvested on day 6, and histology revealed lower expression of both proteins with the fCNT/ siTrp53/siMep1b treatment versus control. The two protein levels in fCNT/siTrp53/siMep1b-treated animals were decreased to near normal concentrations, as determined by enzyme-linked immunosorbent assay results of homogenized kidney tissue (n=3-4). Progression-free survival of injured mice treated with fCNT/ siTrp53/siMep1b was 88% over the 11 days after cisplatin administration, higher than that of all other control groups (including delivery of siRNAs alone). Picrosirius red staining of kidney cortex slices demonstrated a significant reduction of fibrotic tissue formation in fCNT/ siTrp53/siMep1b mice 180 days after injury (p=0.0397). At 11 and 180 days post-injury, fCNT/ siTrp53/siMep1b treatment significantly decreased the density of immune cells in the kidney, as measured by immunostaining for CD3+ T cells, CD45+ lymphocytes, and Iba1+ macrophages (p<0.0059, n=6-9).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Greatest reduction in pregnancy occurs with any contraception

Next Post

Estradiol may be anti-atherosclerotic in early postmenopausal women: the ELITE study

RelatedReports

Depression care collage: a calm woman in a linen shirt beside an empty speech bubble, a steaming teacup and a paper sunrise
Artificial Intelligence

AI health chatbot shows no benefit for perinatal anxiety or depression

November 20, 2026
Soft tissue sarcoma collage: arm muscles with an oval outlined in dotted teal, brass calipers and a folded surgical cap
2MM Trial Briefs

ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma

November 20, 2026
Teen smartphone use collage: a teenage boy in a hoodie looking down at a phone, with empty speech bubbles rising from it
All Specialties

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

November 19, 2026
Physical activity collage: an engraved bicycle, a water bottle lying on its side and a path of flat stepping stones
Artificial Intelligence

AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality

November 19, 2026
Next Post

Estradiol may be anti-atherosclerotic in early postmenopausal women: the ELITE study

Increasing survival rates for patients with acute liver failure

Parathyroidectomy associated with increased bone mineral density and decreased fracture rate in patients with primary hyperparathyroidism

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.